HUP0102400A2 - Szubsztituált oktalidropirido[1,2a]pirazin-származékok, valamint ezeket tartalmazó gyógyászati készítmények - Google Patents
Szubsztituált oktalidropirido[1,2a]pirazin-származékok, valamint ezeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0102400A2 HUP0102400A2 HU0102400A HUP0102400A HUP0102400A2 HU P0102400 A2 HUP0102400 A2 HU P0102400A2 HU 0102400 A HU0102400 A HU 0102400A HU P0102400 A HUP0102400 A HU P0102400A HU P0102400 A2 HUP0102400 A2 HU P0102400A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- disorders
- substituted
- group
- general formula
- Prior art date
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical class C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 206010019233 Headaches Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010050389 Cerebral ataxia Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010034912 Phobia Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 101100321769 Takifugu rubripes htr1d gene Proteins 0.000 abstract 1
- 206010047163 Vasospasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 206010023461 kleptomania Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000019899 phobic disease Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Luminescent Compositions (AREA)
Abstract
A találmány tárgyát az (I) általános képletű vegyületek és ezekettartalmazó gyógyászati készítmények képezik. Az (I) általános képletűvegyületek eredményesen alkalmazhatók emlősöknél különbözőrendellenességek és állapotok kezelésére, ezek közül említhető példáula magas vérnyomás, depresszió, általános szorongásos rendellenesség,fóbia, traumát követő stressz szindróma, elhízottság, kémiaianyagoktól való függőség, fejfájás, migrén, fájdalom, Alzheimer-félebetegség, rögeszmés-kényszeres rendellenességek, pánikbetegség,memória rendellenességek, Parkinson-kór, belső elválasztásúrendellenességek, érgörcs, agyi ataxia, a gyomor- és béltraktusrendellenességei, a skizofrénia negatív szimptómái, a menstruációelőtti szindróma, kleptománia, impotencia, rák, krónikus rohamokbanjelentkező féloldali fejfájás. Az (I) általános képletben aszubsztituensek jelentése az alábbi: R3, R4 és Z jelentése egymástólfüggetlenül például hidrogénatom, halogénatom, így 1-3 fluoratommaladott esetben szubsztituált 1-4 szénatomos alkil-, 1-4 szénatomosalkoxi- vagy (1-4 szénatomos alkoxi)-(1-4 szénatomos alkil)-csoport,amelyben az alkil részek adott esetben 1-3 fluoratommal lehetnekszubsztituálva; W jelentése -CH2-O-(1-6 szénatomos alkil)-csoport,ahol az alkilcsoport egyenes vagy elágazó láncú lehet vagy W jelentése-CH2NR1R2, ahol R1 és R2 jelentése egymástól függetlenül hidrogénatomvagy egyenes vagy elágazó láncú 1-6 szénatomos alkilcsoport, vagy R1és R2 a nitrogénatommal együtt, amelyhez kapcsolódnak telített vagytelítetlen, nem aromás 4-7-tagból álló monociklusos vagy 7-10 tagbólálló biciklusos gyűrűt képezhetnek, amelyek adott esetben az -NR1R2csoporthoz tartozó nitrogénatom mellett egy vagy két továbbiheteroatomot tartalmazhatnak; ahol 1-3 gyűrűtagot képező szénatom vagy1-3 gyűrűtagot képező nitrogénatom adott esetben egymástól függetlenülszubsztituálva lehet. A találmány szerinti vegyületek a szerotonin-1(5-HT) receptorok antagonistái és agonistái és az 5-HT1 D receptorokantagonistái. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8123798P | 1998-04-09 | 1998-04-09 | |
| PCT/IB1999/000457 WO1999052907A1 (en) | 1998-04-09 | 1999-03-18 | Azabicyclic 5ht1 receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0102400A2 true HUP0102400A2 (hu) | 2001-11-28 |
| HUP0102400A3 HUP0102400A3 (en) | 2002-10-28 |
Family
ID=22162936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0102400A HUP0102400A3 (en) | 1998-04-09 | 1999-03-18 | Substituted octalydropyrido[1,2a]pyrazin derivatives and pharmaceutical compositions containing the same |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US6525048B1 (hu) |
| EP (1) | EP1070065B1 (hu) |
| JP (1) | JP3496759B2 (hu) |
| KR (1) | KR100378931B1 (hu) |
| CN (1) | CN1117092C (hu) |
| AP (1) | AP1175A (hu) |
| AR (1) | AR015751A1 (hu) |
| AT (1) | ATE248838T1 (hu) |
| AU (1) | AU749254B2 (hu) |
| BG (1) | BG104915A (hu) |
| BR (1) | BR9909522A (hu) |
| CA (1) | CA2327782A1 (hu) |
| CO (1) | CO5080727A1 (hu) |
| CZ (1) | CZ20003684A3 (hu) |
| DE (1) | DE69910997T2 (hu) |
| DK (1) | DK1070065T3 (hu) |
| DZ (1) | DZ2756A1 (hu) |
| EA (1) | EA003400B1 (hu) |
| ES (1) | ES2204154T3 (hu) |
| HK (1) | HK1035719A1 (hu) |
| HR (1) | HRP20000653A2 (hu) |
| HU (1) | HUP0102400A3 (hu) |
| ID (1) | ID26086A (hu) |
| IL (1) | IL138629A0 (hu) |
| IS (1) | IS5641A (hu) |
| MA (1) | MA26619A1 (hu) |
| MY (1) | MY133390A (hu) |
| NO (1) | NO20005004L (hu) |
| NZ (1) | NZ507010A (hu) |
| OA (1) | OA11496A (hu) |
| PA (1) | PA8469101A1 (hu) |
| PE (1) | PE20000413A1 (hu) |
| PL (1) | PL343408A1 (hu) |
| PT (1) | PT1070065E (hu) |
| SK (1) | SK14782000A3 (hu) |
| TN (1) | TNSN99056A1 (hu) |
| TR (1) | TR200002932T2 (hu) |
| TW (1) | TW555758B (hu) |
| WO (1) | WO1999052907A1 (hu) |
| YU (1) | YU59400A (hu) |
| ZA (1) | ZA992596B (hu) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231833B1 (en) | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| AU762934B2 (en) * | 1999-09-03 | 2003-07-10 | Allergan Sales, Llc | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| GB2362826A (en) * | 2000-06-02 | 2001-12-05 | Lilly Co Eli | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist |
| DE60229123D1 (de) * | 2001-02-20 | 2008-11-13 | Dinan Timothy Gerard | Behandlung von fibromyalgie mit pindolol |
| MXPA05009660A (es) * | 2003-03-12 | 2005-10-20 | Pfizer Prod Inc | Derivados azabiciclicos de piridiloximetilo y bencisoxazol. |
| WO2005082370A1 (en) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders |
| JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
| AR048112A1 (es) | 2004-03-25 | 2006-03-29 | Solvay Pharm Bv | Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor |
| AR049478A1 (es) | 2004-03-25 | 2006-08-09 | Solvay Pharm Bv | Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas. |
| JP2008503560A (ja) * | 2004-06-22 | 2008-02-07 | ファイザー・プロダクツ・インク | ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト |
| EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
| BRPI0514793A (pt) * | 2004-09-10 | 2008-06-24 | Pfizer Prod Inc | uso de derivados azabicìclicos de benzisoxazol e piridiloximetila na preparação de um medicamento para o tratamento de distúrbios cognitivos |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106849A (en) * | 1988-05-24 | 1992-04-21 | American Home Products Corporation | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders |
| WO1990008148A1 (en) * | 1989-01-23 | 1990-07-26 | Pfizer Inc. | Bis-aza-bicyclic anxiolytic agents |
| US5157034A (en) * | 1991-02-27 | 1992-10-20 | Pfizer Inc. | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines |
| CA2118936A1 (en) * | 1991-09-25 | 1993-04-01 | Gene M. Bright | Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines |
| US5262428A (en) * | 1992-03-13 | 1993-11-16 | Wake Forest University | Biologically active tropane derivatives |
| JP2753146B2 (ja) * | 1992-06-16 | 1998-05-18 | ファイザー・インコーポレーテッド | ビス−アザー二環式抗不安薬の製法および中間体 |
| GB9410512D0 (en) * | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
| WO1996010570A1 (en) * | 1994-09-30 | 1996-04-11 | Pfizer Inc. | NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES |
| US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
-
1999
- 1999-03-17 PA PA19998469101A patent/PA8469101A1/es unknown
- 1999-03-18 TR TR2000/02932T patent/TR200002932T2/xx unknown
- 1999-03-18 WO PCT/IB1999/000457 patent/WO1999052907A1/en active IP Right Grant
- 1999-03-18 JP JP2000543464A patent/JP3496759B2/ja not_active Expired - Fee Related
- 1999-03-18 KR KR10-2000-7011167A patent/KR100378931B1/ko not_active IP Right Cessation
- 1999-03-18 US US09/403,892 patent/US6525048B1/en not_active Expired - Fee Related
- 1999-03-18 AT AT99945686T patent/ATE248838T1/de not_active IP Right Cessation
- 1999-03-18 SK SK1478-2000A patent/SK14782000A3/sk unknown
- 1999-03-18 CN CN99807195A patent/CN1117092C/zh not_active Expired - Fee Related
- 1999-03-18 ID IDW20002017A patent/ID26086A/id unknown
- 1999-03-18 YU YU59400A patent/YU59400A/sh unknown
- 1999-03-18 AU AU32687/99A patent/AU749254B2/en not_active Ceased
- 1999-03-18 CA CA002327782A patent/CA2327782A1/en not_active Abandoned
- 1999-03-18 CZ CZ20003684A patent/CZ20003684A3/cs unknown
- 1999-03-18 PL PL99343408A patent/PL343408A1/xx not_active Application Discontinuation
- 1999-03-18 PT PT99945686T patent/PT1070065E/pt unknown
- 1999-03-18 BR BR9909522-0A patent/BR9909522A/pt not_active Application Discontinuation
- 1999-03-18 DK DK99945686T patent/DK1070065T3/da active
- 1999-03-18 NZ NZ507010A patent/NZ507010A/en unknown
- 1999-03-18 EA EA200000910A patent/EA003400B1/ru not_active IP Right Cessation
- 1999-03-18 DE DE69910997T patent/DE69910997T2/de not_active Expired - Fee Related
- 1999-03-18 HU HU0102400A patent/HUP0102400A3/hu unknown
- 1999-03-18 IL IL13862999A patent/IL138629A0/xx unknown
- 1999-03-18 EP EP99945686A patent/EP1070065B1/en not_active Expired - Lifetime
- 1999-03-18 ES ES99945686T patent/ES2204154T3/es not_active Expired - Lifetime
- 1999-04-02 TW TW088105301A patent/TW555758B/zh not_active IP Right Cessation
- 1999-04-05 PE PE1999000270A patent/PE20000413A1/es not_active Application Discontinuation
- 1999-04-07 DZ DZ990057A patent/DZ2756A1/xx active
- 1999-04-07 MY MYPI99001344A patent/MY133390A/en unknown
- 1999-04-07 AR ARP990101572A patent/AR015751A1/es unknown
- 1999-04-07 MA MA25527A patent/MA26619A1/fr unknown
- 1999-04-07 TN TNTNSN99056A patent/TNSN99056A1/fr unknown
- 1999-04-08 AP APAP/P/1999/001502A patent/AP1175A/en active
- 1999-04-08 ZA ZA9902596A patent/ZA992596B/xx unknown
- 1999-04-09 CO CO99021093A patent/CO5080727A1/es unknown
-
2000
- 2000-09-26 IS IS5641A patent/IS5641A/is unknown
- 2000-10-04 HR HR20000653A patent/HRP20000653A2/hr not_active Application Discontinuation
- 2000-10-04 NO NO20005004A patent/NO20005004L/no not_active Application Discontinuation
- 2000-10-06 OA OA1200000273A patent/OA11496A/en unknown
- 2000-11-07 BG BG104915A patent/BG104915A/xx unknown
-
2001
- 2001-09-04 HK HK01106215A patent/HK1035719A1/xx not_active IP Right Cessation
-
2003
- 2003-02-11 US US10/364,804 patent/US6887905B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0102400A2 (hu) | Szubsztituált oktalidropirido[1,2a]pirazin-származékok, valamint ezeket tartalmazó gyógyászati készítmények | |
| HUP0401086A2 (hu) | 4-[(Fenil-piperazinil)-metil]-benzamid-származékok és alkalmazásuk fájdalom, szorongás vagy gasztrointesztinális zavarok kezelésére szolgáló gyógyszerkészítmények előállítására és eljárás a vegyületek előállítására | |
| BG108207A (en) | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| HUP0401307A2 (hu) | 5-HT6 hatással rendelkező új indolszármazékok, eljárás az előállításukra, és ezeket tartalmazó gyógyszerkészítmények | |
| MA26727A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant | |
| HUP0401083A2 (hu) | 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
| HUP0201646A2 (hu) | Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| BR0316883A (pt) | Derivado de piridazin-3(2h)-ona, composto, processo para a preparação de um composto composição farmacêutica, uso do composto, método para o tratamento de um sujeito que está sofrendo de uma condição patológica ou doença susceptìvel de melhora por meio de inibição da fosfodiesterase 4 e produto de combinação | |
| HUP0101031A2 (hu) | Biciklo[2.2.1]heptán-származékok és rokon vegyületek | |
| HUP0001309A2 (hu) | 1-Fenil-4-benzil-piperazinok és a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0401638A2 (hu) | Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények | |
| HUP0303721A2 (hu) | Imidazolilszármazékok mint kortikotropin releasing faktor inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
| MY116280A (en) | A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist | |
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| HUP0401235A2 (hu) | 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| AR019859A1 (es) | Derivados diaza-espiro[3,5]nonano, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y el uso de los mismos para la preparacion de un medicamento | |
| HUP0402341A2 (hu) | Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére | |
| HUP9601680A2 (hu) | Benzizotiazolil-szubsztituált amino-metil-krománok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és a vegyületek alkalmazása | |
| BR0200843A (pt) | Compostos farmaceuticamente ativos | |
| ATE214064T1 (de) | Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| CO5261624A1 (es) | Novedosos derivados fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia | |
| DE60210981D1 (de) | Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase |